Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Vertex Pharmaceuticals Inc

+ Add to Watchlist


125.0800 USD 0.0300 0.02%

As of 20:10:00 ET on 05/22/2015.

Snapshot for Vertex Pharmaceuticals Inc (VRTX)

Open: 124.9100 Day's Range: 124.3300 - 125.9550 Volume: 1,174,654
Previous Close: 125.0500 52wk Range: 63.6800 - 137.5000 1-Yr Rtn: +76.07%

Stock Chart for VRTX

No chart data available.
  • VRTX:US 125.0800
  • 1D
  • 1M
  • 1Y
Interactive VRTX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VRTX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -2.6872
Est. EPS (USD) (12/2015) -1.1150
Est. PEG Ratio -
Market Cap (M USD) 30,488.53
Shares Outstanding (M) 243.75
30 Day Average Volume 1,631,282
Price/Book (mrq) 31.2015
Price/Sale (ttm) 49.3405
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VRTX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for VRTX

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company develops drugs for the treatment of cystic fibrosis, autoimmune diseases, cancer, inflammatory bowel disease, and neurological disorders.

Jeffrey M Leiden "Jeff"President/CEOIan F SmithExec VP/CFO
Stuart A ArbuckleExec VP/Chief Commercial OfcrDavid AltshulerExec VP:Global Research
More Company Profile & Key Executives for VRTX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil